Tumour Immunology Antibodies Page

Tumour immunology studies the complex interactions between cancer cells and the immune system. Research in this field aims to uncover the mechanisms by which the immune system inhibits cancer […]

Tumour Antigens Blog Post

CancerTools.org is committed to empower cancer researchers and the advancement of novel discoveries in tumour immunology by providing relevant research tools, including antibodies targeting tumour antigens. Image: Human breast cancer stained with an antibody to Pax-2. Photo credit: Jason Carroll at the CRI. Tumour antigens are proteins, glycoproteins, glycolipids, or carbohydrates found in tumour cells and recognised by cellular or humoral effectors of the immune system. Tumour antigens are not only useful in identifying cancer cells, they also can be leveraged as targets in cancer therapy. With the ever-increasing potential of tumour antigens in immunotherapy approaches, including cell therapy and cancer vaccines, their discovery and research has become crucial to support successful immunotherapy. Tumour antigens can be classified into tumour-specific antigens and tumour-associated antigens, which in turn can be sub-categorised, based on antigen origin (1,2). Tumour-specific antigens are restricted to tumours and are not found in healthy cells as they are the result of malignant mutations or the expression of viral elements (1,2). They include: > Neoantigens, produced as a direct consequence of genetic alteration caused by tumour DNA mutations and are […]

Anti-p53 [Pab 240] Product

Monoclonal antibody reacts specifically with mutated p53 at an epitope conserved across species and normally hidden within the protein structure in non-mutant forms.
Anti-p53 Pab 240 was created further understand the biochemical role of p53 in cancers and the precise effects of mutation.Anti-p53 (Pab 240) antibody recognises an evolutionary conserved epitope upon p53 hidden within the normal protein structure, however it does not bind to immunoprecipitated wild type p53. This antibody recognises an epitope which is structurally elusive when p53 is in a wildtype conformation but becomes accessible upon denaturation or through mutational conformations where point mutations within the TP53 gene alter the conformational structure of the protein.

Anti-HIF1A [Ha111a] Product

[…] microenvironment or genetic changes, is known to have an important role in the growth of experimental tumours. HIF1A has been observed in varying subsets of tumour cells from various solid tumours.

Anti-p53 [DO-11] Product

Anti-p53 DO-11 antibody recognises the human cellular tumour antigen p53, also known as p53 tumour suppressor protein or NY-CO-13. p53 is a 393 amino acid ~53kDa cytoplasmic/ nuclear protein upregulated […]

Anti-HIV Designer Antigen (DAG19) Product

DAGs ‘designer antigens’ carry epitopes that can lead to the elicitation of broadly neutralising antibodies (bNAbs) in HIV patients. Identification of effective epitopes is a key area of research as […]

Anti-HIV Designer Antigen (DAG23) Product

DAGs ‘designer antigens’ carry epitopes that can lead to the elicitation of broadly neutralising antibodies (bNAbs) in HIV patients. Identification of effective epitopes is a key area of research as […]

Anti-HIV Designer Antigen (DAG16) Product

DAGs ‘designer antigens’ carry epitopes that can lead to the elicitation of broadly neutralising antibodies (bNAbs) in HIV patients. Identification of effective epitopes is a key area of research as […]

Anti-Tumor Necrosis Factor (TNF-a) [12F6] Product

Tumor necrosis factor is a cell signaling protein or cytokine that is involved in inflammation, and specifically one of the proteins in the acute phase reaction.